H. Lundbeck A/S clinical trial pipeline

4 trials changed in the last 30 days: 0 stopped, 3 with notable changes, 1 with a minor change only.

1. Notable

   PROSPECT-2 · Eptinezumab in Adolescents (12-17 Years) With…PROSPECT-2 · Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

   Primary completion pushed from Sep 5, 2026 to Mar 26, 2027

   Also in this update: Trial sites reduced: 83 → 79 locations; Study completion pushed from Oct 31, 2026 to Mar 26, 2027

   H. Lundbeck A/S·Phase 3· NCT04965675· Registry history of NCT04965675 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

2. Notable

   BalanCeD · Lu AG13909 · Cushing's Disease

   Primary completion pushed from Sep 15, 2026 to Aug 10, 2027

   Also in this update: Enrollment closed, study ongoing; Final enrollment: 16 participants (planned 18)

   H. Lundbeck A/S·Phase 2· NCT06471829· Registry history of NCT06471829 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

3. Notable

   Lu AH69593 in Healthy Participants

   Recruitment opened

   H. Lundbeck A/S·Phase 1· NCT07775261· Registry history of NCT07775261 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.